The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Bayer Pharma competitive analysis

Loading summary...

Latest oppositions filed by Bayer Pharma

Explore patent oppositions filed by Bayer Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Nov 13, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP2832350
Method For Producing Disintegrating Particulate Composition Comprising Acid-Type Carboxymethylcellulose, Disintegrating Particulate Composition Comprising Acid-Type Carboxymethylcellulose, And Orally Disintegrating Tablet Including Disintegrating Particulate Composition Comprising Acid-Type CarboxymethylcelluloseDAICELApr 16, 2020
EP3092226
Indazole Compounds As Irak4 InhibitorsAURIGENE DISCOVERYDec 11, 2019
EP2926142
Identification Of Patients In Need Of Pd-L1 Inhibitor CotherapyF HOFFMANN LA ROCHEAug 7, 2019
EP2794635
Ion Exchange Membrane ChromatographyF HOFFMANN LA ROCHEJun 12, 2019
EP2462158
Method To Improve Virus Removal In Protein PurificationF HOFFMANN LA ROCHEOct 10, 2018
EP2322153
Use Of Hif Alpha Stabilizers For Enhancing ErythropoiesisFIBROGENJul 8, 2015

Latest patents of Bayer Pharma opposed by its competitors

Explore Bayer Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP2216055
Jun 18, 2025Medical Device For Dispensing Medicaments5
EP2040683
Aug 16, 2023Pharmaceutical Composition Containing A Tetrahydrofolic Acid1
EP3325013
Jul 19, 2023Stimulators And/Or Activators Of Soluble Guanylate Cyclase (Sgc) In Combination With An Inhibitor Of Neutral Endopeptidase (Nep Inhibitor) And/Or An Angiotensin Aii Antagonist And The Use Thereof1
EP3611169
Jul 21, 2021New Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging1
EP3303307
Sep 4, 2019New Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging1
EP3206873
Dec 12, 2018Laminate Changing Device1
EP1747001
Oct 10, 2018Management Of Breakthrough Bleeding In Extended Hormonal Contraceptive Regimens2
EP2216056
Aug 22, 2018Medical Device For Dispensing Medicaments5
EP1857127
Nov 8, 2017Bolloon Catheter For Paclitaxel-Release4
EP2099453
Sep 6, 2017Combination Therapy Of Substituted Oxazolidinones9

Latest PTAB cases involving Bayer Pharma

Discover the latest PTAB cases involving Bayer Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 15, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Bayer Pharma

IPR2022-01513Sep 9, 2022TEVA PHARMACEUTICALS USABAYER PHARMAFinal Written Decision - Appealed
IPR2022-01515Sep 8, 2022INVAGEN PHARMACEUTICALSBAYER PHARMAFinal Written Decision - Appealed
IPR2022-00517Feb 2, 2022MYLAN PHARMACEUTICALSBAYER PHARMAFinal Written Decision - Appealed

Peer Comparison New

IP litigation analysis comparing Bayer Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BAYER GMBHBAYER PHARMA AKTIENGESELLSCHAFTBAYER ANIMAL HEALTH2 - - -
F HOFFMANN LA ROCHE16140 - -
FIBROGEN116 - 6
GENENTECH - 87 - 65